Testimonial accelopment challenged us, as scientists, to identify why our idea really mattered and required fine detail in every aspect of our proposal. It is in these margins that success can be achieved.
Prof. Dr. Andrew Kellett
ClickGene & NATURE-ETN Project Coordinator
Dublin City University, Ireland

<< Projects

VANGUARD

New Generation Cell Therapy: Bioartificial Pancreas to Cure Type 1 Diabetes

Forty million individuals worldwide suffer from type 1 diabetes. This disease is managed by insulin therapy in a vast majority of patients because of the limited accessibility of beta cell replacement therapies (pancreas or islet of Langerhans transplantation). There is an urgent need for the development of a beta cell replacement therapy that will be available to larger numbers of type 1 diabetic patients.

The VANGUARD project aims to deliver an Advanced Therapeutic Medicinal Product (ATMP) of high translational potential, with properties of increased functionality and implantability and protection from immune destruction. We will construct a bioartificial pancreas by assembling insulin-producing organoids, composed of islet cells, human amniotic epithelial cells (hAEC) and blood outgrowth endothelial cells (BOECs), into an amniotic membrane-derived hydrogel. Components of the amniotic membrane will provide extracellular matrix and mechanical protection and confer their well-defined anti-inflammatory and immunomodulatory properties to the constructs. hAECs will be genome-edited to overexpress and locally release immunomodulatory molecules (HLA-G, HLA-E, CD47 and PD-L1) and endothelial cells will enhance graft revascularization. Functionality, biocompatibility, potency and safety of the bioartificial pancreas will be assessed in vitro and in vivo by implantation in mice reconstituted with a human immune system as pre-clinical model.

The consortium consists of 6 academic institutions with leading scientists in their field, 2 SMEs and 1 NGO with expertise in ethical and social aspects of transplantation.

The ATMP delivered upon completion of the project will provide a model for rapid development of a bioartificial pancreas, utilizing “infinite” sources of insulin-producing cells (stem cell-derived, xenogeneic), and available to all type 1 diabetic patients before they develop the devastating chronic complications of the disease.

Coordinator:
Université de Genève, CH

Partners:

Project




AreaICT
ProgrammeFP7-ICT
Duration01.02.2014 – 31.01.2017
Budget3.2 million euro
More


Proposal Writing



We can support you in writing your next proposal. We are experts in proposal writing, managing the writing process with efficient time-keeping tasks and dealing with the European Commission online tools.

More

Team



Being able to support intrinsically motivated researchers and innovative companies in shaping our future while contributing to their career and business development is both fulfilling and challenging.

Dr. Jeanette Müller
CEO